Develops inhaled drugs for pulmonary hypertension.
Jun 2026Revenue $53.3M/yrExpenses $219M/yr
No trendCash runway ≈ 4 months from Jun 2026
Figures by year
When will Gossamer Bio be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $53.3M and expenses $219M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $48.5M | $219M | −$171M |
| Dec 2024 | $115M | $175M | −$59.9M |
| Dec 2023 | $0.00 | $184M | −$184M |
| Dec 2022 | $0.00 | $219M | −$219M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.